Data as of Nov 28
| -0.04 / -3.33%|
The 1 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +158.62% increase from the last price of 1.16.
The current consensus among 1 polled investment analysts is to Buy stock in InVivo Therapeutics Holdings Corp. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.